New insight into the role of substance P/neurokinin‐1 receptor system in breast cancer progression and its crosstalk with microRNAs

S Ebrahimi, H Javid, A Alaei, SI Hashemy - Clinical genetics, 2020 - Wiley Online Library
The neuropeptide substance P (SP) triggers a variety of tumor‐promoting signaling
pathways through the activation of neurokinin‐1receptor (NK1R), a class of neurokinin G …

Management of chemotherapy-induced nausea and vomiting (CINV): a short review on the role of netupitant-palonosetron (NEPA)

V Lorusso, A Russo, F Giotta, P Codega - Core evidence, 2020 - Taylor & Francis
Introduction Antineoplastic drugs may induce several side effects, including chemotherapy-
induced nausea and vomiting (CINV). Two neurotransmitters play a central role in mediating …

Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity

MF Kabil, MY Mahmoud, AF Bakr, D Zaafar… - Life sciences, 2022 - Elsevier
Breast cancer (BC) is considered the leading cause of mortality and morbidity among adult
women worldwide, and it is associated with many genetic or hormonal factors. Despite the …

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a …

C Weinstein, K Jordan, S Green, S Khanani… - BMC cancer, 2020 - Springer
Background Results from a phase III, randomized, double-blind, active comparator-
controlled, parallel-group trial evaluating fosaprepitant for the prevention of chemotherapy …

Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review

F Vazirian, S Samadi, H Rahimi, M Sadeghi… - Cancer Chemotherapy …, 2022 - Springer
Ifosfamide is one of the chemotherapy regimens which potentially causes neurotoxicity in
patients up to 30%. Aprepitant is administered as an anti-emetic agent in chemotherapy and …

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell …

JS Bubalo, JL Radke, KG Bensch… - Journal of Oncology …, 2024 - journals.sagepub.com
Objective: The purpose of this study was to investigate the efficacy and safety of netupitant/
palonosetron (NEPA) for the prevention of chemotherapy-induced nausea and vomiting …

[HTML][HTML] Intracellular vomit signals and cascades downstream of emetic receptors: Evidence from the least shrew (Cryptotis parva) model of vomiting

W Zhong, NA Darmani - Remedy open access, 2017 - ncbi.nlm.nih.gov
Nausea and vomiting are often considered as stressful symptoms of many diseases and
drugs. In fact they are the most feared and debilitating side-effects of many cancer …

A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic

X Wang, ZY Zhang, J Wang… - Clinical Pharmacology in …, 2019 - Wiley Online Library
This 2‐part study evaluated the QT/QTc prolongation potential and safety and
pharmacokinetics of the antiemetic rolapitant, a neurokinin‐1 receptor antagonist. Part 1 was …

[PDF][PDF] Cindy Weinstein1, Karin Jordan2, Stuart Green1, Saleem Khanani3, Elizabeth Beckford-Brathwaite1

W Vallejos, A Pong, SJ Noga, BL Rapoport - 2020 - bmccancer.biomedcentral.com
Background: Results from a phase III, randomized, double-blind, active comparator-
controlled, parallel-group trial evaluating fosaprepitant for the prevention of chemotherapy …

The protagonist is a neurokinin 1, 3 antagonist

JS Carpenter - Menopause, 2020 - journals.lww.com
Although vasomotor symptoms (VMS) are a ubiqui-tous problem for perimenopausal and
postmenopausal women, 1-3 effective and well-tolerated treatment options are somewhat …